亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

医学 宫颈癌 疫苗效力 宫颈上皮内瘤变 血清状态 临床终点 代理终结点 临床试验 随机对照试验 内科学 妇科 接种疫苗 肿瘤科 癌症 免疫学 病毒载量 人类免疫缺陷病毒(HIV)
作者
Matti Lehtinen,Jorma Paavonen,Cosette M. Wheeler,Unnop Jaisamrarn,Suzanne M. Garland,Xavier Castellsagué,S. Rachel Skinner,Dan Apter,Paulo Naud,Jorge Salmerón,Song-Nan Chow,Henry C Kitchener,Júlio César Teixeira,James Hedrick,Genara Limson,Anne Szarewski,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,Newton Sérgio de Carvalho,Maria Julieta V. Germar,Klaus Peters,Adrian Mindel,P. De Sutter,F. Xavier Bosch,Marie-Pierre David,Dominique Descamps,Frank Struyf,Gary Dubin
出处
期刊:Lancet Oncology [Elsevier]
卷期号:13 (1): 89-99 被引量:654
标识
DOI:10.1016/s1470-2045(11)70286-8
摘要

Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate endpoint used in licensure trials of human papillomavirus (HPV) vaccines. Vaccine efficacy against CIN3+, the immediate precursor to invasive cervical cancer, is more difficult to measure because of its lower incidence, but provides the most stringent evidence of potential cancer prevention. We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young Adults).Healthy women aged 15-25 years with no more than six lifetime sexual partners were included in PATRICIA, irrespective of their baseline HPV DNA status, HPV-16 or HPV-18 serostatus, or cytology. Women were randomly assigned (1:1) to receive an HPV-16/18 AS04-adjuvanted vaccine or a control hepatitis A vaccine via an internet-based central randomisation system using a minimisation algorithm to account for age ranges and study sites. The patients and study investigators were masked to allocated vaccine. The primary endpoint of PATRICIA has been reported previously. In the present end-of-study analysis, we focus on CIN3+ and AIS in the populations of most clinical interest, the total vaccinated cohort (TVC) and the TVC-naive. The TVC comprised all women who received at least one vaccine dose, approximating catch-up populations and including sexually active women (vaccine n=9319; control=9325). The TVC-naive comprised women with no evidence of oncogenic HPV infection at baseline, approximating early adolescent HPV exposure (vaccine n=5824; control=5820). This study is registered with ClinicalTrials.gov, number NCT00122681.Vaccine efficacy against CIN3+ associated with HPV-16/18 was 100% (95% CI 85·5-100) in the TVC-naive and 45·7% (22·9-62·2) in the TVC. Vaccine efficacy against all CIN3+ (irrespective of HPV type in the lesion and including lesions with no HPV DNA detected) was 93·2% (78·9-98·7) in the TVC-naive and 45·6% (28·8-58·7) in the TVC. In the TVC-naive, vaccine efficacy against all CIN3+ was higher than 90% in all age groups. In the TVC, vaccine efficacy against all CIN3+ and CIN3+ associated with HPV-16/18 was highest in the 15-17 year age group and progressively decreased in the 18-20 year and 21-25 year age groups. Vaccine efficacy against all AIS was 100% (31·0-100) and 76·9% (16·0-95·8) in the TVC-naive and TVC, respectively. Serious adverse events occurred in 835 (9·0%) and 829 (8·9%) women in the vaccine and control groups, respectively; only ten events (0·1%) and five events (0·1%), respectively, were considered to be related to vaccination.PATRICIA end-of-study results show excellent vaccine efficacy against CIN3+ and AIS irrespective of HPV DNA in the lesion. Population-based vaccination that incorporates the HPV-16/18 vaccine and high coverage of early adolescents might have the potential to substantially reduce the incidence of cervical cancer.GlaxoSmithKline Biologicals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李爱国应助fdj3121采纳,获得10
23秒前
激动的似狮完成签到,获得积分10
24秒前
30秒前
科研通AI2S应助科研通管家采纳,获得10
44秒前
eplga完成签到,获得积分10
58秒前
1分钟前
fdj3121发布了新的文献求助10
1分钟前
fdj3121完成签到,获得积分10
1分钟前
MROU应助Who采纳,获得10
1分钟前
2分钟前
竹子完成签到,获得积分10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
3分钟前
3分钟前
pegasus0802完成签到,获得积分10
4分钟前
andrele发布了新的文献求助20
4分钟前
MROU应助李子潭采纳,获得40
4分钟前
www268完成签到 ,获得积分10
4分钟前
孤独的大灰狼完成签到 ,获得积分10
4分钟前
完美世界应助神奇圆滑手采纳,获得10
5分钟前
Krim完成签到 ,获得积分10
5分钟前
5分钟前
5分钟前
Benhnhk21完成签到,获得积分10
6分钟前
6分钟前
6分钟前
wanci应助迷人幻波采纳,获得10
7分钟前
8分钟前
8分钟前
8分钟前
迷人幻波发布了新的文献求助10
8分钟前
奔跑石小猛完成签到,获得积分10
8分钟前
NOTHING完成签到 ,获得积分10
8分钟前
充电宝应助迷人幻波采纳,获得10
8分钟前
8分钟前
linyingo发布了新的文献求助10
8分钟前
nadia完成签到,获得积分10
9分钟前
迷人幻波完成签到,获得积分20
9分钟前
9分钟前
paradox完成签到 ,获得积分10
9分钟前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Cognitive Paradigms in Knowledge Organisation 2000
Effect of reactor temperature on FCC yield 2000
Near Infrared Spectra of Origin-defined and Real-world Textiles (NIR-SORT): A spectroscopic and materials characterization dataset for known provenance and post-consumer fabrics 610
Promoting women's entrepreneurship in developing countries: the case of the world's largest women-owned community-based enterprise 500
Shining Light on the Dark Side of Personality 400
Introduction to Spectroscopic Ellipsometry of Thin Film Materials Instrumentation, Data Analysis, and Applications 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3307414
求助须知:如何正确求助?哪些是违规求助? 2941030
关于积分的说明 8500232
捐赠科研通 2615428
什么是DOI,文献DOI怎么找? 1428900
科研通“疑难数据库(出版商)”最低求助积分说明 663595
邀请新用户注册赠送积分活动 648461